Bristol-Myers Squibb Co
(LTS:0R1F)
$
59.4
-0.61 (-1.02%)
Market Cap: 119.70 Bil
Enterprise Value: 163.01 Bil
PE Ratio: 0
PB Ratio: 6.98
GF Score: 82/100 Bristol-Myers Squibb Co at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022 / 12:10PM GMT
Release Date Price:
$75.62
(+8.39%)
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Great. Good morning, everybody. Thanks for joining us today. I'm Terence Flynn, the pharma analyst at Morgan Stanley. Just first on disclosures. For important disclosures, please see the Morgan Stanley research website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
This morning, I'm very pleased to be hosting Bristol-Myers. Today from the company, we have Chris Boerner, who is Executive Vice President and Chief Commercial Officer. Thanks for joining us, Chris.
Christopher S. Boerner
Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
Happy to be here.
Questions & Answers
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
So before I get into the congratulations on deucrava or SOTYKTU, which we are just
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot